H.C. Wainwright analyst Emily Bodnar assumed coverage of TG Therapeutics (TGTX) with a Buy rating and $60 price target The firm expects Briumvi’s market penetration to grow significantly in the next few years. The company is building a franchise in the treatment of multiple sclerosis, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TG announces updated data presentations from ULTIMATE I, II Phase 3 trials
- TG Therapeutics price target raised to $55 from $53 at B. Riley
- TG Therapeutics says enrollment commenced for Phase 3 trial of BRIUMVI
- Alphabet jumps after avoiding worst case in antitrust ruling: Morning Buzz
- TG Therapeutics completes share repurchase program, authorize new $100M program